AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 22835011
Drug: High-level FK778
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-level FK778 (H) 4 x 600 mg/day (4 days) followed by 120 mg/day
Trial: 22835011
Drug: Mid-level FK778
RxNorm normalized name: peanut allergenic extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mid-level FK778 (M) 3 x 600 mg/day (3 days) followed by 110 mg/day
Trial: 22835011
Drug: Low-level FK778
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-level FK778 (L) 2 x 600 mg/day (2 days) followed by 100 mg/day
Trial: 22835011
Drug: MMF 1
RxNorm normalized name: MMF
DrugBank: Monomethyl fumarate (DB14219)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MMF 1 g/day (Control)
Trial: 19238303
Drug: Genistein (54
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Genistein (54 mg/die)
Trial: 9676147
Drug: Karaoke therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Karaoke therapy
Trial: 31600271
Drug: Can do
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Can do treatment (CDT)
Trial: 28854538
Drug: Dexmedetomidine delivered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexmedetomidine delivered via target-controlled infusion
Trial: 25599735
Drug: Atorvastatin, 20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atorvastatin, 20 mg/d
Trial: 25599735
Drug: Atorvastatin with
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atorvastatin with NER, 500 mg/d
Trial: 12756424
Drug: 2 mg
RxNorm normalized name: iodine 2 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 mg nicotine tooth patch (NTP)
Trial: 12756424
Drug: 4 mg
RxNorm normalized name: lutein 4 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 mg nicotine tooth patch (NTP)
Trial: 12756424
Drug: 4.3 mg
RxNorm normalized name: menthol 4.3 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4.3 mg nicotine tooth patch (NTP)
Trial: 10319446
Drug: Individually administered
RxNorm normalized name: chloroxylenol
DrugBank: Chloroxylenol (DB11121)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Individually administered mood induction procedure
Trial: 10319446
Drug: Group administered
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group administered mood induction procedure
Trial: 81586
Drug: Supervised toothbrushing
RxNorm normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Supervised toothbrushing every second week during the school year, using a disclosing solution.
Trial: 31196132
Drug: Standard treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard treatment plus clindamycin for 7 days
Trial: 31196132
Drug: Standard treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard treatment (flucloxacillin/cefazolin for MSSA; vancomycin/daptomycin for MRSA)
Trial: 28327804
Drug: Amphotericin B
RxNorm normalized name: Amphotericin B
DrugBank: Amphotericin B (DB00681)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Amphotericin B deoxycholate (1 mg/kg/day for 14 days)
Trial: 19179026
Drug: Oral conjugated
RxNorm normalized name: Conjugated Estrogens
DrugBank: Conjugated estrogens (DB00286)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral conjugated estrogen 0.625mg/day
Trial: 19179026
Drug: Intranasal 300microg/day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intranasal 300microg/day estradiol hemihidrate
Trial: 19179026
Drug: Percutaneous gel
RxNorm normalized name: ALCOHOL 62 mL in 100 mL PERCUTANEOUS GEL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Percutaneous gel 1.5mg/day estradiol hemihidrate
Trial: 11440787
Drug: Bretschenider solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bretschenider solution (HTK)
Trial: 7972649
Drug: Relaxation therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Relaxation therapy with respiratory feedback (RFB)
Trial: 2656335
Drug: 10 mg
RxNorm normalized name: biotin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg famotidine twice daily
Trial: 28600210
Drug: Accelerated epirubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Accelerated epirubicin (100 mg/m2 every 2 weeks with 6 mg pegfilgrastim on day 2)
Trial: 28600210
Drug: Standard epirubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard epirubicin (100 mg/m2 every 3 weeks)
Trial: 28600210
Drug: Capecitabine (2500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Capecitabine (2500 mg/m2, 1250 mg/m2 given twice daily on days 1-14 of each cycle)
Trial: 28600210
Drug: CMF (600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CMF (600 mg/m2 cyclophosphamide, 40 mg/m2 methotrexate, 600 mg/m2 fluorouracil)
Trial: 9786563
Drug: Nimodipine (30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nimodipine (30 mg, two capsules)
Trial: 9786563
Drug: Placebo (two
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (two identical appearing capsules)
Trial: 8156351
Drug: Levovist 300
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Levovist 300 mg/ml (10 ml intravenous injection)
Trial: 2845188
Drug: Sodium valproate
RxNorm normalized name: sodium valproate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sodium valproate (single dose and long term administration)
Trial: 27085768
Drug: Social cognitive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Social cognitive theory‐based weight‐management treatments emphasizing physical activity‐derived self‐regulation (n=53)
Trial: 25521188
Drug: 20 g
RxNorm normalized name: PEG-20 glyceryl oleate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 g SQ-LNS with varying contents of zinc
Trial: 25521188
Drug: Dispersible tablet
RxNorm normalized name: Aspirin 75 mg orodispersible tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dispersible tablet containing 0 or 5 mg zinc
Trial: 23764385
Drug: Lithium treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lithium treatment (mean blood level 0.67 mEq/L)
Trial: 21343159
Drug: Intravenous lidocaine
RxNorm normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous lidocaine 2% (1.5 mg kg(‐1) bolus at induction followed by 2.0 mg kg(‐1) h(‐1) infusion)
Trial: 17609296
Drug: Testosterone (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Testosterone (200 mg every 2 weeks by intramuscular injection with placebo pill daily)
Trial: 17609296
Drug: Testosterone plus
RxNorm normalized name: Testosterone
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Testosterone plus Finasteride (200 mg of T every 2 weeks by intramuscular injection with 5 mg of finasteride daily)
Trial: 17609296
Drug: Placebo (placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (placebo injections and pills)
Trial: 15728645
Drug: Acute insulin-glucose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acute insulin-glucose infusion followed by insulin-based long-term glucose control (Group 1)
Trial: 15728645
Drug: Insulin-glucose infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Insulin-glucose infusion followed by standard glucose control (Group 2)
Trial: 2696506
Drug: Bupivacaine 0.5%
RxNorm normalized name: BUPivacaine 0.5% injectable kit
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bupivacaine 0.5% plus fentanyl 75 mcg
Trial: 1104246
Drug: 0.2% chlorhexidine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.2% chlorhexidine gluconate solution, twice a day
Trial: 21838784
Drug: itraconazole 100
RxNorm normalized name: itraconazole 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: itraconazole 100 mg
Trial: 21838784
Drug: gemfibrozil-itraconazole combination
RxNorm normalized name: Gemfibrozil
DrugBank: Gemfibrozil (DB01241)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: gemfibrozil-itraconazole combination
Trial: 20578781
Drug: Insulin glargine
RxNorm normalized name: Insulin Glargine
DrugBank: Insulin glargine (DB00047)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Insulin glargine plus oral antidiabetes drugs (OADs)
Trial: 20578781
Drug: Premixed insulin
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Premixed insulin only
Trial: 16087029
Drug: Dexamethasone inner
RxNorm normalized name: Dexamethasone
DrugBank: Dexamethasone acetate (DB14649)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Dexamethasone inner ear perfusion (4 mg/mL)
Trial: 12600856
Drug: Iron supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Iron supplementation (10 mg Fe, 5 d/wk for 6 mo)
Trial: 12600856
Drug: Zinc supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zinc supplementation (10 mg Zn, 5 d/wk for 6 mo)
Trial: 12600856
Drug: Beta-carotene supplementation
RxNorm normalized name: Beta Carotene
DrugBank: Beta carotene (DB06755)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Beta-carotene supplementation (2.4 mg beta-carotene, 5 d/wk for 6 mo)
Trial: 12600856
Drug: Iron +
RxNorm normalized name: Celebrate Iron + C
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Iron + Zinc supplementation (10 mg each, 5 d/wk for 6 mo)
Trial: 11214351
Drug: Vitamin A,
RxNorm normalized name: Vitamin A, D
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin A, 3 mg retinol equivalent/day
Trial: 8626351
Drug: Valproate (given
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Valproate (given twice daily)
Trial: 8626351
Drug: Placebo (given
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (given twice daily)
Trial: 6429875
Drug: Conventional Oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional Oral Nutritional Support (CN)
Trial: 24456057
Drug: Standard physical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard physical therapy modalities
Trial: 24456057
Drug: Both groups
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both groups (Virtual reality and Standard physical therapy)
Trial: 22689471
Drug: 400 mL
RxNorm normalized name: Lantidra 400 ML Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 400 mL FV-puree-based drink (FVPD)
Trial: 10609985
Drug: Trimeprazine tartrate
RxNorm normalized name: Trimeprazine Tartrate
DrugBank: Alimemazine (DB01246)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Trimeprazine tartrate 15 mg/5 mL
Trial: 10609985
Drug: Trimeprazine tartrate
RxNorm normalized name: Trimeprazine Tartrate
DrugBank: Alimemazine (DB01246)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Trimeprazine tartrate 30 mg/5 mL
Trial: 8538895
Drug: Intranasal midazolam
RxNorm normalized name: Midazolam
DrugBank: Midazolam (DB00683)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Intranasal midazolam 0.5 mg/kg
Trial: 8538895
Drug: Rectal midazolam
RxNorm normalized name: Midazolam
DrugBank: Midazolam (DB00683)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Rectal midazolam 0.5 mg/kg
Trial: 1650015
Drug: GM-CSF during
RxNorm normalized name: axatilimab-csfr
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GM-CSF during chemotherapy
Trial: 1650015
Drug: Chemotherapy without
RxNorm normalized name: threonine
DrugBank: Threonine (DB00156)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Chemotherapy without GM-CSF
Trial: 6345596
Drug: Triple regimen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Triple regimen (chlorthalidone 25 mg/day, oxdralazine 20 mg/day, propranolol 40 mg/day)
Trial: 6345596
Drug: Double regimen
RxNorm normalized name: Anacin Aspirin Regimen Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Double regimen (chlorthalidone 25 mg/day, propranolol 103 mg/day)
Trial: 6345596
Drug: Triple regimen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Triple regimen (chlorthalidone 25 mg/day, oxdralazine 56 mg/day, propranolol 112 mg/day)
Trial: 6345596
Drug: Double regimen
RxNorm normalized name: Anacin Aspirin Regimen Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Double regimen (chlorthalidone 25 mg/day, propranolol 222 mg/day)
Trial: 23203821
Drug: IFN‐K (30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IFN‐K (30 μg, 60 μg, 120 μg, or 240 μg)
Trial: 19506491
Drug: Pressure therapy
RxNorm normalized name: AerobiKA Oscillating Positive Expiratory Pressure Therapy System
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pressure therapy (PT) group
Trial: 16790659
Drug: 30 mg
RxNorm normalized name: agar 30 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 mg of 1% preservative free 2‐chloroprocaine
Trial: 16790659
Drug: 40 mg
RxNorm normalized name: rutin 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40 mg of 1% preservative free 2‐chloroprocaine
Trial: 16790659
Drug: 50 mg
RxNorm normalized name: talc 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 mg of 1% preservative free 2‐chloroprocaine
Trial: 8418720
Drug: Caudal nerve
RxNorm normalized name: nerve growth factor
DrugBank: Nerve Growth Factor (DB12620)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Caudal nerve block with 0.25% bupivacaine, 0.75 mL/kg (group I)
Trial: 8418720
Drug: Caudal nerve
RxNorm normalized name: nerve growth factor
DrugBank: Nerve Growth Factor (DB12620)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Caudal nerve block with 0.25% bupivacaine and 1:200,000 epinephrine, 0.75 mL/kg (group II)
Trial: 3511376
Drug: Antacid treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antacid treatment (suspension, 400 mg, one and three hours after meals)
Trial: 3511376
Drug: Cimetidine (400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cimetidine (400 mg, twice a day)
Trial: 29796595
Drug: Crushed and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Crushed and suspended TRI with oral intake of enteral nutrition
Trial: 29796595
Drug: Whole-tablet TRI
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Whole-tablet TRI with fasting
Trial: 22722651
Drug: Intravenous lacosamide
RxNorm normalized name: Lacosamide
DrugBank: Lacosamide (DB06218)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Intravenous lacosamide (15-min infusion)
Trial: 22722651
Drug: Intravenous lacosamide
RxNorm normalized name: Lacosamide
DrugBank: Lacosamide (DB06218)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Intravenous lacosamide (30-min infusion)
Trial: 22722651
Drug: Intravenous lacosamide
RxNorm normalized name: Lacosamide
DrugBank: Lacosamide (DB06218)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Intravenous lacosamide (60-min infusion)
Trial: 22722651
Drug: Oral lacosamide
RxNorm normalized name: Lacosamide
DrugBank: Lacosamide (DB06218)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Oral lacosamide (tablet)
Trial: 20542574
Drug: Treatment as
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment as usual (n=461)
Trial: 19901570
Drug: 90-day Web-based
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 90-day Web-based treatment program
Trial: 11136208
Drug: 2 mg
RxNorm normalized name: iodine 2 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 mg diazepam up to three times daily
Trial: 9249647
Drug: COX-2 inhibitor
RxNorm normalized name: COX-2 inhibitor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: COX-2 inhibitor (celecoxib)
Trial: 7943770
Drug: i.m. MID
FDA approved: no
EMA approved: no
PMDA approved: no
Description: i.m. MID (0.08 mg/kg) and i.v. FENT (MidFent group)
Trial: 3107849
Drug: FAM (standard
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FAM (standard doses of 5-fluorouracil, adriamycin, and mitomycin-C)
Trial: 3107849
Drug: Hi-FAM (high
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hi-FAM (high doses of 5-fluorouracil, adriamycin, and mitomycin-C)
Trial: 29508635
Drug: Levothyroxine/liothyronine combination
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Levothyroxine/liothyronine combination therapy
Trial: 22305534
Drug: Formula enriched
RxNorm normalized name: STRESS FORMULA 500,BIOTIN ENRICHED TAB
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Formula enriched with milk fat globule membrane (INPULSE), 200 mL daily for 4 months
Trial: 7869208
Drug: Ca gluconate-glycerophosphate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ca gluconate-glycerophosphate preparation (group CaGP)
Trial: 2374358
Drug: Intensive macrofractional
RxNorm normalized name: Uricalm Intensive
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intensive macrofractional irradiation (25 Gr cumulative local dose)
Trial: 2374358
Drug: Combined treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined treatment (radiotherapy and surgery with local UHF hyperthermia)
Trial: 204971
Drug: INH 5
RxNorm normalized name: INH 50 MG Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: INH 5 mg/kg body weight + RMP 10 mg/kg body weight + EMB 25 mg/kg body weight daily
Trial: 204971
Drug: INH 15
RxNorm normalized name: INH 150 MG Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: INH 15 mg/kg body weight + RMP 10 mg/kg body weight + EMB 40 mg/kg body weight, intermittent administration (2/7)
Trial: 3599226
Drug: Intramuscular injection
RxNorm normalized name: rabies, intramuscular injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intramuscular injection of 150 mg netilmicin sulfate 1 hour preoperatively
Trial: 3599226
Drug: Intramuscular injection
RxNorm normalized name: rabies, intramuscular injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intramuscular injection of 1.5 ml of 0.9% sodium chloride 1 hour preoperatively
Trial: 31920016
Drug: Oral zabofloxacin
RxNorm normalized name: marbofloxacin Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral zabofloxacin for the treatment of COPD exacerbations
Trial: 26150070
Drug: Oxytocin nasal
RxNorm normalized name: oxytocin Nasal Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oxytocin nasal spray (24IU)
Trial: 16689000
Drug: Salpingostomy combined
RxNorm normalized name: combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Salpingostomy combined with Bushen Huoxue Decoction (BHD), 1 dose every day starting from the 5th day of menstrual cycle for 14 days, with hydrotubation using Xiangdan Injection (XI) applied once in the next menstrual cycle after salpingostomy.
Trial: 16689000
Drug: Salpingostomy alone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Salpingostomy alone with hydrotubation using Xiangdan Injection (XI).
Trial: 8708654
Drug: Aspirin low
RxNorm normalized name: Aspirin Low Dose
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Aspirin low dose (< 100 mg per day)
Trial: 8708654
Drug: Aspirin medium
RxNorm normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Aspirin medium dose (300 to 325 mg per day)
Trial: 8708654
Drug: Aspirin high
RxNorm normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Aspirin high dose (> 900 mg per day)
Trial: 1424410
Drug: 200 mg
RxNorm normalized name: RNA 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 mg toloxatone three times a day
Trial: 1424410
Drug: 400 mg
RxNorm normalized name: mesna 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 400 mg toloxatone three times a day
Trial: 3936106
Drug: Baclofen (30‐90
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Baclofen (30‐90 mg per day)
Trial: 18158708
Drug: Control (no
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (no ACE inhibitor)
Trial: 15122049
Drug: Vaccine 'X'
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vaccine 'X'
Trial: 10024259
Drug: Omeprazole 10
RxNorm normalized name: omeprazole 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Omeprazole 10 mg or 20 mg daily for 2 weeks
Trial: 10024259
Drug: Ranitidine 150
RxNorm normalized name: ranitidine 150 MG
DrugBank: Ranitidine (DB00863)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ranitidine 150 mg twice daily for 2 weeks
Trial: 10024259
Drug: Intermittent treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intermittent treatment overall
Trial: 7580003
Drug: Depot leuprorelin
RxNorm normalized name: leuprorelin
DrugBank: Leuprolide (DB00007)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Depot leuprorelin (3.75 mg IM injection)
Trial: 7580003
Drug: Daily buserelin
RxNorm normalized name: buserelin
DrugBank: Buserelin (DB06719)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily buserelin (0.3 mg SC twice daily)
Trial: 2134562
Drug: Cimetidine intermittent
RxNorm normalized name: Cimetidine
DrugBank: Cimetidine (DB00501)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cimetidine intermittent infusion (300 mg every 8 hours)
Trial: 2134562
Drug: Cimetidine intermittent
RxNorm normalized name: Cimetidine
DrugBank: Cimetidine (DB00501)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cimetidine intermittent infusion (300 mg every 6 hours)
Trial: 2134562
Drug: Cimetidine continuous
RxNorm normalized name: Cimetidine
DrugBank: Cimetidine (DB00501)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cimetidine continuous infusion (600 mg per day)
Trial: 2134562
Drug: Cimetidine continuous
RxNorm normalized name: Cimetidine
DrugBank: Cimetidine (DB00501)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cimetidine continuous infusion (900 mg per day)
Trial: 2134562
Drug: Cimetidine continuous
RxNorm normalized name: Cimetidine
DrugBank: Cimetidine (DB00501)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cimetidine continuous infusion (1200 mg per day)
Trial: 6159711
Drug: 4-drug regimen
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 4-drug regimen (streptomycin, isoniazid, rifampicin, pyrazinamide) for 2 months followed by thiacetazone plus isoniazid for 6 months